Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression

被引：28

作者：

Mondello, Patrizia ^{[1
,3
]}

Cuzzocrea, Salvatore ^{[2
]}

Navarra, Michele ^{[2
,4
]}

Mian, Michael ^{[5
]}

机构：

[1] Univ Messina, Dept Human Pathol, Messina, Italy

[2] Univ Messina, Dept Chem, Biol, Pharmaceut & Environm Sci, Messina, Italy

[3] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, New York, NY USA

[4] Hosp Bolzano, Dept Hematol & Ctr Bone Marrow Transplantat, Bolzano, Italy

[5] Med Univ Innsbruck, Dept Internal Med, Hematol Oncol, Innsbruck, Austria

来源：

ONCOTARGET | 2017年 / 8卷 / 12期

关键词：

multiple myeloma; micro-environment; therapeutic opportunities; osteoclast activation; angiogenesis; ENDOTHELIAL GROWTH-FACTOR; SOLUBLE INTERLEUKIN-6 RECEPTOR; FACTOR-KAPPA-B; MATRIX-METALLOPROTEINASE INHIBITOR; MESENCHYMAL STROMAL CELLS; PREDICTS POOR-PROGNOSIS; SKELETAL-RELATED EVENTS; MULTIPLE-MYELOMA; HUMAN CD38; ZOLEDRONIC ACID;

D O I：

10.18632/oncotarget.14610

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite the advent of many therapeutic agents, such as bortezomib and lenalidomide that have significantly improved the overall survival, multiple myeloma remains an incurable disease. Failure to cure is multifactorial and can be attributed to the underlying genetic heterogeneity of the cancer and to the surrounding micro-environment. Understanding the mutual interaction between myeloma cells and micro-environment may lead to the development of novel treatment strategies able to eradicate this disease. In this review we discuss the principal molecules involved in the micro-environment network in multiple myeloma and the currently available therapies targeting them.

引用

页码：20394 / 20409

页数：16

共 177 条

[1] Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion
Abe, M
Hiura, K
Wilde, J
Shioyasono, A
Moriyama, K
Hashimoto, T
Kido, S
Oshima, T
Shibata, H
Ozaki, S
Inoue, D
Matsumoto, T
[J]. BLOOD, 2004, 104 (08) : 2484 - 2491
[2] AbuJawdeh GM, 1996, LAB INVEST, V74, P1105
[3] Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)
Achen, MG
Jeltsch, M
Kukk, E
Mäkinen, T
Vitali, A
Wilks, AF
Alitalo, K
Stacker, SA
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) : 548 - 553
[4] INTERLEUKIN-6 IN BIOLOGY AND MEDICINE
AKIRA, S
TAGA, T
KISHIMOTO, T
[J]. ADVANCES IN IMMUNOLOGY, VOL 54, 1993, 54 : 1 - 78
[5] Interleukin-10 Induces Both Plasma Cell Proliferation and Angiogenesis in Multiple Myeloma
Alexandrakis, Michael G.
Goulidaki, Nektaria
Pappa, Constantina A.
Boula, Anna
Psarakis, Fotios
Neonakis, Ioannis
Tsirakis, George
[J]. PATHOLOGY & ONCOLOGY RESEARCH, 2015, 21 (04) : 929 - 934
[6] A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
Anderson, DM
Maraskovsky, E
Billingsley, WL
Dougall, WC
Tometsko, ME
Roux, ER
Teepe, MC
DuBose, RF
Cosman, D
Galibert, L
[J]. NATURE, 1997, 390 (6656) : 175 - 179
[7] ANDERSON KC, 1989, BLOOD, V73, P1915
[8] CD8+CD28- T cells:: Certainties and uncertainties of a prevalent human T-cell subset
Arosa, FA
[J]. IMMUNOLOGY AND CELL BIOLOGY, 2002, 80 (01) : 1 - 13
[9] The increase of IFN-γ production through aging correlates with the expanded CD8+highCD28-CD57+ subpopulation
Bandrés, E
Merino, J
Vázquez, B
Inogés, S
Moreno, C
Subirá, ML
Sánchez-Ibarrola, A
[J]. CLINICAL IMMUNOLOGY, 2000, 96 (03) : 230 - 235
[10] Metalloproteinases in multiple myeloma: Production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells
Barille, S
Akhoundi, C
Collette, M
Mellerin, MP
Rapp, MJ
Harousseau, JL
Bataille, R
Amiot, M
[J]. BLOOD, 1997, 90 (04) : 1649 - 1655

← 1 2 3 4 5 6 7 8 9 10 →